转移性去势敏感型前列腺癌的治疗选择进展。
The evolving options in metastatic castration-sensitive prostate cancer.
机构信息
Centre Hospitalier de l'Université de Montréal, Montréal, Canada.
出版信息
Curr Opin Support Palliat Care. 2020 Sep;14(3):270-275. doi: 10.1097/SPC.0000000000000507.
PURPOSE OF REVIEW
Leading trials CHAARTED, STAMPEDE, GETUG-AFU15 and LATITUDE established docetaxel and abiraterone acetate addition to androgen deprivation therapy (ADT) as a treatment guideline for patients with metastatic castration-sensitive prostate cancer.
RECENT FINDINGS
Two recent combinations, enzalutamide with ADT and apalutamide with ADT were tested in metastatic castration-sensitive prostate cancer in three randomized controlled trials. Both combinations provided survival gain, expanding our options of treatment. Moreover, additional evidence behind radiotherapy for the primary tumor in metastatic prostate cancer is emerging.
SUMMARY
In this updated article, we review the data of these trials and highlight the distinctions between these therapies, in order to better personalize the care for patients with metastatic prostate cancer.
目的综述
主要试验 CHAARTED、STAMPEDE、GETUG-AFU15 和 LATITUDE 确立了多西他赛和醋酸阿比特龙联合雄激素剥夺疗法（ADT）作为转移性去势敏感前列腺癌患者的治疗指南。
最新发现
最近两项临床试验，恩扎鲁胺联合 ADT 和阿帕鲁胺联合 ADT，在转移性去势敏感前列腺癌中进行了测试。这两种联合治疗均提供了生存获益，扩大了我们的治疗选择。此外，转移性前列腺癌中原发肿瘤放疗的更多证据正在出现。
总结
在这篇更新的文章中，我们回顾了这些试验的数据，并强调了这些治疗方法之间的差异，以便为转移性前列腺癌患者提供更个性化的治疗。
Zotero 插件